ENLV
Enlivex Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$0.21
+1.17%Oct 19, 2026, 12:17 UTC
Enlivex announced a cost-reduction plan effective immediately to reduce cash burn and focus resources on its Phase 2b Allocetra trial for knee osteoarthritis.
Source:Sep 22, 2026, 12:00 UTC
Enlivex Ltd. terminated its previously announced financing that was payable in RAIN tokens.
Source:Jul 31, 2026, 15:25 UTC
Enlivex, a Nasdaq-listed biotech company, is seeking shareholder approval to authorize up to $800 million in financing, potentially increasing share count by up to 951%, with proceeds primarily used to acquire the RAIN crypto token for treasury purposes.
Source:Jul 28, 2026, 12:00 UTC
Enlivex announced a private placement of $400,000,000 of ordinary shares to a single institutional investor.
Source:Jul 13, 2026, 12:00 UTC
Enlivex received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for Allocetra in age-related knee osteoarthritis.
Source:Jul 7, 2026, 12:00 UTC
Enlivex Ltd. announced a 1-for-15 reverse stock split of its ordinary shares, effective July 9, 2026.
Source: